Point72 Asset Management
PCRX icon

Point72 Asset Management’s Pacira BioSciences PCRX Stock Holding History

Point72 Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-150,000
Closed -$6.85M – 1073
2017
Q4 		$6.85M Sell
150,000
-632,200
-81% -$25.1M 0.03% 528
2017
Q3 		$29.4M Buy
+782,200
New +$31.5M 0.13% 192

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Point72 Asset Management's PCRX Position: Q1 2025 in Review

Point72 Asset Management sold out of Pacira BioSciences (PCRX) in Q1 2025, closing a stake of 1,075,673 shares — an estimated $20.3M sold.

Point72 Asset Management first reported a position in PCRX in Q2 2016 and held it in 17 quarters. The position peaked at $50.6M in Q2 2019. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.

  • Point72 Asset Management reported no remaining Pacira BioSciences position as of Q1 2025 after selling out during the quarter.
  • Point72 Asset Management sold 1,075,673 Pacira BioSciences shares in Q1 2025, an estimated $20.3M.
  • Point72 Asset Management first reported a position in Pacira BioSciences in Q2 2016 and held it in 17 quarters.
  • Point72 Asset Management's Pacira BioSciences position peaked at $50.6M in Q2 2019.
  • 235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.

Based on Point72 Asset Management's 13F filing for Q1 2025, filed 15 May 2025.